<DOC>
	<DOCNO>NCT00905255</DOCNO>
	<brief_summary>The purpose study compare benefit risk lixisenatide ( AVE0010 ) use 2-step initiation regimen 1-step initiation regimen Japan , period 24 week treatment , follow extension Week 76 . The primary objective study evaluate safety lixisenatide daily treatment monotherapy Week 24 descriptive comparison 1-step initiation 2-step initiation regimen patient type 2 diabetes Japan . The secondary objective assess overall safety lixisenatide daily treatment monotherapy Week 52 Week 76 ; assess effect lixisenatide glycosylated hemoglobin ( HbA1c ) reduction Week 52 Week 76 , body weight , fast plasma glucose ( FPG ) ; assess pharmacokinetics ( PK ) anti-lixisenatide antibody development .</brief_summary>
	<brief_title>GLP-1 Receptor Agonist Lixisenatide Patients With Type 2 Diabetes Glycemic Control Safety Evaluation Monotherapy ( GETGOAL-MONO Japan LTS )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes mellitus , diagnose least 2 month time screen visit , treat antidiabetic agent 3 month screen , except treatment sulfonylureas alphaglucosidase inhibitor stable dose . In case oral antidiabetic treatment must discontinue start singleblind runin phase HbA1c le ( &lt; ) 7 percent ( % ) great ( &gt; ) 10 % screen At time screen age &lt; legal age majority Pregnant breastfeed woman woman childbearing potential effective contraceptive method Type 1 diabetes mellitus Type 2 diabetes treat antidiabetic pharmacological agent ( except sulfonylurea alphaglucosidase inhibitor stable dose ) within 3 month precede screening . Insulin use accept within 3 month prior screen visit follow reason : ) Prior insulin use management gestational diabetes ; b ) Shortterm ( less equal [ &lt; = ] 1 month ) insulin use maintain glycemic control hospitalization , medical procedure , intervention FPG screen &gt; 250 milligram per deciliter ( mg/dL ) ( &gt; 13.9 millimole per liter [ mmol/L ] ) Weight change 5 kilogram ( kg ) 3 month precede screen visit History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease History metabolic acidosis , include diabetic ketoacidosis within 1 year prior screen Hemoglobinopathy hemolytic anemia , receipt blood plasma product within 3 month prior time screen Within last 6 month prior screen : history myocardial infarction , stroke , heart failure require hospitalization Known history drug alcohol abuse within 6 month prior time screen Cardiovascular , hepatic , neurological , endocrine disease , active malignant tumor major systemic disease patient short life expectancy make implementation protocol interpretation study result difficult , history presence clinically significant diabetic retinopathy , history presence macular edema likely require laser treatment within study period Uncontrolled inadequately control hypertension time screen rest supine systolic diastolic blood pressure &gt; 180 millimeter mercury ( mmHg ) &gt; 95 mmHg , respectively Laboratory finding time screening : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) : &gt; 2 time upper limit normal ( ULN ) laboratory range ; amylase and/or lipase : &gt; 3 time ULN ; total bilirubin : &gt; 1.5 time ULN ( except case Gilbert 's syndrome ) ; hemoglobin &lt; 11 gram/deciliter and/or neutrophil &lt; 1500 per cubic millimeter ( mm^3 ) and/or platelet &lt; 100000/mm^3 ; positive test Hepatitis B surface antigen ( HBsAg ) and/or Hepatitis C antibody ( HCAb ) positive serum pregnancy test female childbearing potential Any clinically significant abnormality identify physical examination , laboratory test , electrocardiogram ( ECG ) vital sign time screen judgment investigator subinvestigator precludes safe completion study constrain efficacy assessment Patients consider investigator subinvestigator inappropriate study reason ( example , impossibility meet specific protocol requirement , schedule visit , able selfinjections , likelihood require treatment screen phase treatment phase drug permit clinical study protocol ) Patient investigator subinvestigator , pharmacist , study coordinator , study staff relative thereof directly involve conduct protocol Use systemic glucocorticoid ( exclude topical application inhale form ) 1 week within 3 month prior time screen Use investigational drug within 3 month prior screen Participation previous study lixisenatide Endstage renal disease define serum creatinine clearance &lt; 15 milliliter/minute ( calculate Cockcroft Gault formula ) and/or patient dialysis Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , include , limited gastroparesis gastroesophageal reflux disease require medical treatment , within 6 month prior time screen Allergic reaction glucagon like peptide1 ( GLP1 ) agonist past ( example , exenatide , liraglutide ) metacresol Additional exclusion criterion end runin phase : informed consent withdrawal ( patient willing continue fail return ) ; lack compliance singleblind placebo runin phase ( &gt; 2 injection miss ) ; patient adverse event precludes inclusion study , assess Investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>hyperglycemia</keyword>
	<keyword>GLP-1</keyword>
</DOC>